1L ESCC ORR, mDoR, and mPFS
Improved ORR, mDoR, and mPFS in patients with 1L ESCC and PD-L1 scores ≥1%1
Additional efficacy outcomes in 1L ESCC: ORR, DoR, and PFS in PD-L1 ≥1%
Image description
Additional efficacy outcomes:
TEVIMBRA + chemotherapy demonstrated an overall response rate of 58% (95% CI: 51%-65%) vs 36% with placebo + chemotherapy (95% CI: 30%-42%).
TEVIMBRA + chemotherapy increased median duration of response to 7.2 months (95% CI: 6.2-9.6) vs 5.7 months with placebo + chemotherapy (95% CI: 4.4-7.3).
TEVIMBRA + chemotherapy extended median progression-free survival to 7.2 months vs 5.5 months with placebo + chemotherapy
[HR: 0.56 (95% CI: 0.45-0.70)].
Limitation: Additional efficacy outcomes were not powered for statistical comparison and are descriptive only. No definitive conclusions can be drawn.
Frequently Asked Questions
What was the response rate with TEVIMBRA in patients with 1L advanced ESCC and PD-L1 scores ≥1?
TEVIMBRA + chemotherapy demonstrated an overall response rate* of 58% vs 36% with placebo + chemotherapy. Additionally, TEVIMBRA + chemotherapy extended duration of response* to 7.2 months vs 5.7 months with placebo + chemotherapy. 1
*ORR and DoR were additional efficacy outcomes in this trial.1
What was the PFS with TEVIMBRA in patients with 1L advanced ESCC and PD-L1 scores ≥1%?
TEVIMBRA + chemotherapy reported extended median progression-free survival* of 7.2 months vs 5.5 months with placebo + chemotherapy.1
*PFS was an additional efficacy outcome in this trial.1
Reference: 1. TEVIMBRA. Prescribing Information. BeOne Medicines USA, Inc.; 2026.